Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Molnupiravir  COVID-19 treatment studies for Molnupiravir  C19 studies: Molnupiravir  Molnupiravir   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent: 
0 0.5 1 1.5 2+ Hospitalization 46% Improvement Relative Risk Improvement, day 14 46% Improvement, day 10 52% Improvement, day 5 25% Viral clearance, day 14 59% Viral clearance, day 10 81% Viral clearance, day 5 78% c19early.org/m Tippabhotla et al. Molnupiravir for COVID-19 RCT EARLY Favors molnupiravir Favors control
Efficacy and Safety of Molnupiravir for the Treatment of Non-Hospitalized Adults With Mild COVID-19: A Randomized, Open-Label, Parallel-Group Phase 3 Trial
Tippabhotla et al., SSRN Electronic Journal, doi:10.2139/ssrn.4042673
24 Feb 2022    Source   PDF   Share   Tweet
RCT 1,220 patients in India, showing lower risk of hospitalization and improved recovery with treatment. CTRI/2021/07/034588.
Concerns have been raised that the mutagenic mechanism of action may create dangerous variants or cause cancer [Hadj Hassine, Swanstrom].
risk of hospitalization, 46.2% lower, RR 0.54, p = 0.26, treatment 7 of 610 (1.1%), control 13 of 610 (2.1%), NNT 102, day 28.
risk of no improvement, 46.4% lower, RR 0.54, p < 0.001, treatment 67 of 610 (11.0%), control 125 of 610 (20.5%), NNT 11, day 14.
risk of no improvement, 52.3% lower, RR 0.48, p < 0.001, treatment 199 of 610 (32.6%), control 417 of 610 (68.4%), NNT 2.8, day 10.
risk of no improvement, 24.8% lower, RR 0.75, p < 0.001, treatment 433 of 610 (71.0%), control 576 of 610 (94.4%), NNT 4.3, day 5.
risk of no viral clearance, 59.2% lower, RR 0.41, p < 0.001, treatment 42 of 610 (6.9%), control 103 of 610 (16.9%), NNT 10.0, day 14.
risk of no viral clearance, 81.0% lower, RR 0.19, p < 0.001, treatment 62 of 610 (10.2%), control 327 of 610 (53.6%), NNT 2.3, day 10.
risk of no viral clearance, 77.6% lower, RR 0.22, p < 0.001, treatment 113 of 610 (18.5%), control 505 of 610 (82.8%), NNT 1.6, day 5.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Tippabhotla et al., 24 Feb 2022, Randomized Controlled Trial, India, peer-reviewed, 5 authors, study period 1 July, 2021 - 24 August, 2021, average treatment delay 3.0 days.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperMolnupiravirAll
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit